Abstract
The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (-3.1%; SD = 19.9; F[1,19]=5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F[1,19]=5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F[1,19]=12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F[1,19]=4.2, p=0.06) and IL-18 (29.1%; SD = 64; F[1,19]=5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.
| Original language | English (US) |
|---|---|
| Article number | 1751583 |
| Journal | Evidence-based Complementary and Alternative Medicine |
| Volume | 2018 |
| DOIs | |
| State | Published - Jan 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Complementary and alternative medicine
Cite this
The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease. / Lewis, John E; Atlas, Steven E.; Higuera, Oscar L.; Fiallo, Andrea; Rasul, Ammar; Farooqi, Ashar; Kromo, Olga; Lantigua, Laura A.; Tiozzo, Eduard; Woolger, Judi; Goldberg, Sharon; Mendez, Armando J; Rodriguez, Allan E; Konefal, Janet.
In: Evidence-based Complementary and Alternative Medicine, Vol. 2018, 1751583, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease
AU - Lewis, John E
AU - Atlas, Steven E.
AU - Higuera, Oscar L.
AU - Fiallo, Andrea
AU - Rasul, Ammar
AU - Farooqi, Ashar
AU - Kromo, Olga
AU - Lantigua, Laura A.
AU - Tiozzo, Eduard
AU - Woolger, Judi
AU - Goldberg, Sharon
AU - Mendez, Armando J
AU - Rodriguez, Allan E
AU - Konefal, Janet
PY - 2018/1/1
Y1 - 2018/1/1
N2 - The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (-3.1%; SD = 19.9; F[1,19]=5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F[1,19]=5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F[1,19]=12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F[1,19]=4.2, p=0.06) and IL-18 (29.1%; SD = 64; F[1,19]=5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.
AB - The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (-3.1%; SD = 19.9; F[1,19]=5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F[1,19]=5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F[1,19]=12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F[1,19]=4.2, p=0.06) and IL-18 (29.1%; SD = 64; F[1,19]=5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.
UR - http://www.scopus.com/inward/record.url?scp=85048205472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048205472&partnerID=8YFLogxK
U2 - 10.1155/2018/1751583
DO - 10.1155/2018/1751583
M3 - Article
AN - SCOPUS:85048205472
VL - 2018
JO - Evidence-based Complementary and Alternative Medicine
JF - Evidence-based Complementary and Alternative Medicine
SN - 1741-427X
M1 - 1751583
ER -